### **Overview** **GlobalSpace Technologies Ltd** is a prominent Indian digital technology company operating at the intersection of **HealthTech and EdTech**, with a renewed strategic focus on building AI-driven, integrated solutions for the healthcare and pharmaceutical sectors. Originally incorporated in 2010, the company has undergone a significant transformation over recent years, divesting from non-core areas and repositioning itself as a leading SaaS and AI-powered health-tech platform provider. As of FY 2024–25, GlobalSpace generates over **85% of its revenue** from its flagship AI-enhanced healthcare platforms — **DocExa** and **MediOla** — marking a full pivot toward high-margin, scalable digital health solutions. --- ### **Core Business Segments** #### **1. HealthTech – AI-Powered Digital Health Platforms** GlobalSpace offers a suite of cloud-based, AI-integrated platforms serving pharmaceutical companies, doctors, distributors, and patients. Its health-tech ecosystem is designed to digitize and streamline operations across the pharmaceutical and healthcare value chain. ##### **Flagship Platforms:** - **DocExa**: An AI-enabled virtual consultation platform launched in 2018, now serving over 60,000 doctors. Initially adopted rapidly during the pandemic, it enables physicians to set up personalized virtual clinics within 48 hours. Features include mobile EMR, AI-driven decision support, secure data encryption (AS2-level), teleconsultations, and virtual detailing. - Strategic partnerships with major pharma firms: **Cadila, Macleods, and Pfizer**. - Collaborations with medical associations: **FOGSI, CCI, and FOGSI** to expand specialist networks in OB-GYN, cardiology, chest medicine, and diabetology. - Launched **DocExa Social**, **DocExa VD**, and vaccine registration features to enhance user engagement. - Monetization: Subscription fees per doctor, % of consultation fees, analytics for pharma clients, advertising, and virtual detailing. - **MediOla**: A physician engagement and content delivery platform that leverages AI analytics to provide data-driven insights to pharmaceutical clients. It optimizes medical content dissemination and improves HCP (Healthcare Professional) interaction. - Integral to client marketing and compliance strategies. - Generates significant revenue through licensing and analytics services. - **VODO Suite**: A **SaaS-based CRM and Sales Force Automation (SFA/CLM)** platform used by 14+ pharma companies to manage sales reps, marketing campaigns, and field force productivity. - Positioned as the first unified platform linking pharma sales teams with distributors, chemists, and doctors. - Offers analytics dashboards and mobile device management. - Charges per rep per month and generates incremental revenue from advanced analytics. - **Mediapp**: A B2B digital distribution network connecting over **48,000 pharmacies** and 800+ stockists. It digitizes supply chain operations for pharma distributors and retailers. - Commission-based revenue model with added streams from analytics and advertising. - Integrated with DocExa and VODO to form a cohesive ecosystem. --- #### **2. Artificial Intelligence & Generative AI – Strategic Growth Driver** Artificial intelligence is now central to GlobalSpace’s growth strategy, with multiple AI-enhanced platforms contributing directly to revenue and differentiation. ##### **Key AI Initiatives:** - **AI Integration in Core Platforms (FY 2024–25):** Both **DocExa** and **MediOla** were enhanced with AI analytics during the year, improving physician engagement, personalization, and market adoption. - **PATGPT – Pharma-Specific Large Language Model (LLM)** Launched in **September 2025**, PATGPT represents a major milestone in GlobalSpace’s product evolution: - A **hybrid-trained LLM**: 50% pre-trained on proprietary pharmaceutical data by GlobalSpace; 50% customized using client-specific data in secure cloud environments. - Functions as both a **ready-to-deploy AI product** and a **custom LLM training service**. - **Applications**: - *Current*: Sales & marketing optimization, inventory & distribution analytics. - *Future Roadmap*: Expansion into **R&D**, **clinical trials**, **pharmacovigilance**, and **regulatory submissions**. - Positions GlobalSpace as a pioneer in domain-specific enterprise AI for pharma. --- #### **3. Entry into Digital Therapeutics & Hardware (2024)** In early 2024, GlobalSpace made a strategic move beyond software into **digital therapeutics and wearable hardware** with the launch of **GoRoga**. - **GoRoga**: - India’s **first anti-stress wearable device** for individuals with moderate to severe stress and anxiety. - FDA-approved, using **Non-Invasive Brain Stimulation (NIBS)** technology powered via smartphone. - Targets neurological modulation: reduces **beta waves** (anxiety), enhances **alpha and theta waves** (calm & relaxation). - Delivered through earpad electrodes with 20–60 min daily usage recommended over 3–4 weeks. - Priced at **₹22,500**, includes one year of **Elite subscription** to the Roga App. - Available on **Amazon and Razorpay**, with EMI options. - **GoRoga App & Analytics Dashboard**: - Offers **GAD-7 assessments**, stress tracking, progress scoring, and AI-driven insights. - Elite tier includes **live consultations with psychiatrists/psychologists**, guided audio-visual programs co-developed with therapists. - Subscription model: **Premium and Elite tiers**. - Significance: Marks entry into **regulated digital therapeutics** and showcases integration of **hardware + software + AI + clinical content** — a first for the company. --- #### **4. Mergers, Acquisitions & Strategic Growth** - **Acquisition of Innopharm Healthcare Pvt Ltd (Mar 2024 & Aug 2024):** - A contract sales organization serving top-tier pharma clients. - Allows **cross-selling** of GlobalSpace’s digital platforms (VODO, MediOla) to Innopharm’s established clientele. - Strengthens pharma tech offerings and expands service footprint. - **Merger of Mediapp with DocExa (Completed by mid-2021):** - Created an integrated **online-offline healthcare ecosystem**, connecting doctors (DocExa) with local pharmacies (Mediapp). - Enabled e-prescription fulfillment via neighborhood e-pharmacies, increasing platform stickiness. - **Strategic MoU – Cardiovascular Disease Screening Program (Feb 2025):** - Partnered with **MOD3RN Care** (Australia/India-based digital health firm) and **GE Healthcare** to jointly bid for Maharashtra’s **$400 million AI-driven cardiovascular screening initiative**. - GlobalSpace contributes its **AI platform**, while GE provides **diagnostic hardware**. - Represents a shift toward **large-scale public health AI programs** and potential global replication. --- ### **EdTech Segment & Subsidiary: Makebot** While the company has strategically focused on health tech, its **EdTech arm continues to operate through Makebot**, a subsidiary and India’s leading **STEAM (Science, Technology, Engineering, Arts, Mathematics) education platform**. - Serves **1,200+ schools** and **145,000+ students** across India. - Offers **coding, robotics, AI, and machine learning** curricula using a hardware-software integrated model. - Flagship product: **'m tiny' robot** for students in grades 4–12. - Revenue model: Subscription-based learning, STEAM kits, certification programs, and online Olympiads (e.g., NSTO). - International expansion: Signed MoUs with **7 partners** across **Malaysia, Singapore, Indonesia, Australia, NZ, and Dubai**. - Aligned with **National Education Policy 2020** (coding from Grade 6), creating long-term tailwinds. *Note: Though EdTech remains a subsidiary operation, health tech now dominates strategy and revenue.* --- ### **Financial Performance & Growth Trends** - **FY 2022–23**: >110% YoY revenue growth; 100% from health/pharma tech. - **FY 2023–24**: >65% revenue growth; over **90% from DocExa and MediOla**. - **FY 2024–25**: Over **85% of revenue from AI-powered platforms** (DocExa & MediOla), with growing contribution from PATGPT and GoRoga. - R&D investments focused on enhancing AI capabilities and expanding platform ecosystems. --- ### **Technology & Partnerships** - **Core Technologies**: Cloud, mobility, big data, AI/ML, robotics, IoT. - **Strategic Alliances**: - **Pfizer** (adult vaccine awareness via DocExa) - **Cadila & Macleods** (platform adoption) - **GE Healthcare & MOD3RN Care** (public health AI) - **Makeblock, Intel, Microsoft** (EdTech credibility)